PartnershipJul 13, 2026, 01:02 PM
Cosmos Health partners Libytec for DIABIT-IS X launch in Greece
AI Summary
Cosmos Health Inc. announced a five-year partnership with Libytec Pharmaceutical S.A. to commercialize its type-2 diabetes medication, DIABIT-IS X (sitagliptin phosphate), in Greece. Cosmos Health will supply the generic alternative to Merck's Januvia®, while Libytec handles distribution and promotion. This agreement is expected to significantly contribute to Cosmos Health's revenue and cash flow, broadening its reach in the European sitagliptin market through Greece's national health insurance system.
Key Highlights
- Cosmos Health partnered with Libytec for DIABIT-IS X commercialization in Greece.
- Five-year agreement for distribution and promotion of the type-2 diabetes medication.
- DIABIT-IS X is a generic alternative to Merck's Januvia® (sitagliptin).
- Branded Januvia® and Janumet® generated approximately $4.5 billion in 2022.
- Partnership expected to contribute meaningfully to Cosmos Health's revenue and cash flow.
- Product will be accessible via Greece's national health insurance system (EOPYY).
- Positions Cosmos Health for expansion into other European markets.
Price Impact
More from COSM